2: Recent advances in therapy of diabetes

Medical Journal of Australia

Volumn 179, Issue 8, 2003, Pages 441-447

  Couper, Jennifer J ^a,b   Prins, Johannes B ^c,d  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDASE IV INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HUMALOG MIX25; HUMAN INSULIN; HUMULIN 20 80; HUMULIN 30 70; HUMULIN 50 50; HUMULIN L; HUMULIN NPH; HUMULIN UL; INCRETIN DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SECRETAGOGUE DERIVATIVE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MIXTARD 20 80; MIXTARD 30 70; MIXTARD 50 50; NEUTRAL INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROSOL; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FLUID RETENTION; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN PUMP; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LOW DRUG DOSE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; POSTPRANDIAL STATE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUPPORT GROUP; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0142260956     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05628.x     Document Type: Review

References (24)

1. American Diabetes Association. Implications of the Diabetes Control and Complications Trial (position statement). Diabetes Care 2003; 26: 25-27.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
3. White NH, Cleary PA, Dahms W, et al. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after conclusion of the Diabetes Control and Complications Trial (DCCT). Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications. J Pediatr 2001; 139: 1923-1928.
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
5. Hoey H, Aanstoot HJ, Chiraelli F. Good metabolic control is associated with better quality of life in 2101 adolescents with type 1 diabetes. Diabetes Care 2001; 24: 1923-1928.
6. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycaemia during sleep. N Engl J Med 1998; 338: 1057-1062.
7. Wang F, Carabino JM, Vergara CM. Insulin glargine: A systematic review of long acting insulin analogue. Clin Ther 2003; 259: 1541-1577.
8. King AB, Armstrong D. A comparison of basal insulin delivery. Diabetes Care 2003; 26: 1322.
9. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: A meta-analysis. Diabetes Care 2003; 2694: 1079-1087.
10. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327.
11. Ludvigsson J, Haas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients. Pediatrics 2003; 111: 933-938.
12. Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001; 107: 222-226.
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
14. Craig ME, Handelsman P, Donaghue KC, et al. Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust 2002; 177: 235-238.
15. Grey EA, Boland M, Davidson J, et al. Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr 2000; 137: 107-113.
16. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low glycemic index diets in the management of diabetes: A meta-analysis of randomized controlled trials. Diabetes Care 2003; 26: 2261-2267.
17. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care 2003; 26: 138-143.
18. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24: 643-645.
19. Shaw JE, Chisholm DJ. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003; 179: 379-383.
20. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: New drugs for an old disease. Med J Aust 2002; 176: 381-386.
21. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: Rationale for rational use of insulin. Mayo Clin Proc 2003; 78: 411-413.
22. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
23. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003; 63: 1165-1184.
24. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372.